Clinical Trial Detail

NCT ID NCT03697304
Title Platform Trial Evaluating Safety and Efficacy of BI 754091 Anti- PD-1 Based Combination Therapies in PD-(L)1 naïve and PD- (L)1 Pretreated Patient Populations With Advanced/Metastatic Solid Tumours.
Recruitment Suspended
Gender both
Phase Phase II
Variant Requirements No
Sponsors Boehringer Ingelheim
Indications

gastric adenocarcinoma

Advanced Solid Tumor

gastroesophageal adenocarcinoma

Therapies

BI 754091

BI 754111

Age Groups: senior adult

No variant requirements are available.